Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nicotine pouch study reveals how much gets into your blood

NCT ID NCT05452278

Knowledge-focused Sponsor: Imperial Brands PLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested four different nicotine pouches (tobacco-free and tobacco-containing) in 27 healthy adults who regularly use snus or nicotine pouches. Researchers measured how much nicotine entered the bloodstream and how much was left in the pouch after 20 minutes of use. The goal was to compare nicotine delivery between products, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nicotine
What this could lead to
If successful, this study could help understand how different nicotine pouches deliver nicotine to the body, informing product labeling or regulation.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. Results may not apply to all users or predict long-term health effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

Oct 2021

Finished

Jul 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI ≥ 18.0 and ≤ 30.0 kg/m2 * Clinically normal medical history * User of snus or nicotine pouches for ≥1 year, with a minimum weekly use of 2 or more snus or nicotine pouch cans and who is willing and considered able to use brands with nicotine content in the range of 14 to 20 mg nicotine/pouch Exclusion Criteria: * History of any clinically significant disease or disorder * Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first use of IP. * Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and HIV * Female subjects who are pregnant or breastfeeding * Presence or history of drug or alcohol abuse * Excessive caffeine consumption defined by a daily intake of \>5 cups of caffeine containing beverages * Intend to change nicotine-use habit or make a quit attempt within the next 3 months from the screening visit.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers

Contacts and locations

Locations

  • CTC Clinical Trial Consultants AB

    Uppsala, SE-752 37, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.